HSCSW News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

HS

Mkt Cap

N/A

Volume

6

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Thermo Fisher to Report Q3 Earnings: What's in the Cards?Thermo Fisher Scientific is set to report Q3 2026 results on October 21, with consensus estimates projecting 7.1% revenue growth to $11.91B and 10.5% EPS growth to $6.40. The company's Life Sciences Solutions and Laboratory Products segments are expected to drive growth at 10.1% and 9.8% respectively, supported by recent product innovations. However, Specialty Diagnostics revenues are projected to decline 3% following the sale of its microbiology business to Astorg for $1.075 billion.Zacks Investment Research · Oct 13, 2026

HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue EstimatesHeartSciences Inc. (HSCS) reported a quarterly loss of $0.86 per share, missing the consensus estimate of $0.78 loss by 10.26%. The company posted zero revenues, missing estimates by 97.9%. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market. The Medical Info Systems industry ranks in the top 34% of Zacks industries.Zacks Investment Research · Sep 14, 2026

HeartSciences Announces Conference Participation and Investor WebinarHeartSciences Inc. will host an Investor Webinar and present at the Emerging Growth Conference 85 on August 20, 2025, to provide updates on their AI-powered medical technology for ECG/EKG analysis.GlobeNewswire Inc. · Aug 15, 2025

HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial MilestoneHeartSciences, an AI-powered medical technology company, announced its first commercial customer for the MyoVista Insights platform, Westcliffe Health Innovations in the U.K. This partnership aims to enhance ECG management and improve healthcare efficiency.GlobeNewswire Inc. · May 29, 2025

HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter ProgramHeartSciences, an AI-powered medical technology company, has launched the MyoVista Insights platform, a cloud-native ECG management system designed to enhance clinical decision-making and healthcare IT efficiency. The platform features AI-ECG algorithms, streamlined workflows, and advanced cybersecurity.GlobeNewswire Inc. · May 1, 2025

HeartSciences Regains Compliance with Nasdaq Listing RequirementsSouthlake, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that on June 3, 2024, the Company received formal notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC indicating that HeartSciences has regained compliance with bid price requirement as set forth in Listing Rule 5550(a)(2), and that the Company is therefore in compliance with the Nasdaq Capital Market’s listing requirements and the scheduled hearing has now been cancelled.GlobeNewswire Inc. · Jun 4, 2024

HeartSciences to Present at the LD Micro Invitational XIV ConferenceSouthlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York. Mr. Simpson will also be hosting one-on-one meetings through the conference.GlobeNewswire Inc. · Apr 2, 2024

HeartSciences Reports Third Quarter Fiscal 2024 Financial ResultsSouthlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.GlobeNewswire Inc. · Mar 14, 2024

HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 DiabetesData Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and ARIC HF score, the conventional standards of care for Stage B Heart Failure screening Data Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and ARIC HF score, the conventional standards of care for Stage B Heart Failure screeningGlobeNewswire Inc. · Mar 12, 2024

HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet TechnologySouthlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Canadian Intellectual Property Office Application No. 3,000,369 has been granted by the Canadian Intellectual Property Office.GlobeNewswire Inc. · Mar 6, 2024

HS

HSCSWHeartSciences Inc. Warrant

HSCSW

Pay with—

Available Balance0.00

Your PositionYou don't own any HSCSW yet.

Related Tickers

Earnings